emmanuel onaivi
William Paterson University
Wayne, United States
Chief Editor
Advances in Drug and Alcohol Research
Main content
Chief editors
Mission & scope
ADAR’s mission is to utilize INRC and IDARS’ multidisciplinary expertise, technological advancements and translational tools to enhance collaboration of scientists around the world not only to improve drug and alcohol abuse therapeutics, but to seek diverse cell, gene and proteomic, neuro-immuno-microbiome targets to treat drug addiction.
An outstanding Editorial Board of international researchers supports the Editor-in-Chief Emmanuel Onaivi, a Professor at William Paterson University in New Jersey USA. This multidisciplinary Open Access journal welcomes and will publish original manuscripts, commentaries, reviews on all drugs of abuse using diverse in-vitro and in-vivo molecular, cellular and systems biological approaches in pre-clinical models and clinical studies. Special issues and section editors will be dedicated to highlight key areas of psychostimulant, opiates, alcohol, cannabis and cannabinoids, hallucinogens and psychiatric co-morbidities along with the growing food and digital addictions.
The journal of Advances in Drug and Alcohol Research will use Frontiers’ transformative Open Access platform and aims to be the global Open Access leader in all fields of the science of drug and alcohol abuse and addiction. All publications receive objective and rigorous peer-review processes. Furthermore, ADAR aims to bring together drug and alcohol abuse scientists and clinicians from across the globe to share and discuss the current state of knowledge, challenges and the future of drug addiction that continues to be a global problem. Frontiers’ transparent peer-review approach allows authors to interact with reviewers and editors to improve the articles for publication.
ADAR would like to recognize Dr Michael Kuhar, Emeritus Professor and Editor, has contributed to many publications with IDARS over the years.
Journal Information
Short name
Adv. Drug Alcohol Res.
Abbreviation
adar
Electronic ISSN
2674-0001
PMCID
All published articles receive a PMCID
Indexed in
1Science, Bielefeld Academic Search Engine (BASE), Chinese Academy of Sciences GoOA, CLOCKSS, CNKI Scholar, CrossRef, DeepGreen, Dimensions, DOAJ, EBSCO, Figshare, Google Scholar, Jisc, MyScienceWork, Norwegian Register, OpenAIRE, PubMed, PubMed Central (PMC), Semantic Scholar, Sherpa/Romeo
Editorial Board:
Editor-in-Chief
Emmanuel Onaivi, William Paterson University, Wayne, United States
Deputy Editor-in-Chief
Lee-Yuan Liu-Chen, Temple University, Philadelphia, United States
Emeritus Associate Editors
Abdelouahhab Tazi, Faculty of Medicine & Pharmacy, University of Hassan II Casablanca, Casablanca, Morocco
Associate Editors
Ream Al-Hasani, Washington University in St. Louis, St. Louis, United States
Declan Ali, University of Alberta, Edmonton, Canada
Syed Ali, National Center for Toxicological Research, Jefferson, United States
Chris Bailey, University of Bath, Bath, United Kingdom
Andrea Bedini, University of Bologna, Bologna, Italy
Alicia Brusco, CONICET, Buenos Aires, Argentina
Shilpa Buch, University of Nebraska Medical Center, Obama, United States
Anna Bukiya, University of Tennessee Health Science Center, Memphis, United States
Jean Lud Cadet, National Institute on Drug Abuse, Bethesda, United States
Catherine Cahill, California State University, Los Angeles, United States
Sulie Chang, Seton Hall University, South Orange, United States
Lih-Chu Chiou, National Taiwan University, Taipei, Taiwan
Macdonald Christie, The University of Sydney, Darlington, Australia
Brian Cox, Uniformed Services University, Bethesda, United States
Fulton Crews, University of North Carolina, Chapel Hill, United States
Nissar Darmani, Western University of Health Sciences, Pomona, United States
Lakshmi Devi, Icahn School of Medicine at Mt. Sinai, New York, United States
Alex Dopico, University of Tennessee Health Science Ctr., Memphis, United States
Ephrem Engidawork, Addis Ababa University, Addis Ababa, Ethiopia
Eliot Gardner, National Institute on Drug Abuse, Bethesda, United States
Nicholas Gilpin, Louisiana State University, New Orleans, United States
Frank Hall, University of Toledo, Toledo, United States
Lucia Hipolito, University of Valencia, Valencia, Spain
Hiroki Ishiguro, University of Yamanashi, Kofu, Japan
Chloe Jordan, McLean Hospital, Belmont, United States
George Koob, National Institute on Alcohol Abuse & Alcoholism, Bethesda, United States
Michael Kuhar, Emory University, Atlanta, United States
Edward Levin, Duke University, Durham, United States
Z. Karl Lin, Harvard Medical School, Boston, United States
Qing-Rong Liu, National Institute on Aging (NIH), Bethesda, United States
Irwin Lucki, Uniformed Services University, Bethesda, United States
Kabirullah Lutfy, Western University of Health Sciences, Pomona, United States
Pierre-Eric Lutz, Centre National de la Recherche Scientifique, Paris, France
Jorge Manzanares, Miguel Hernandez University of Elche, Elche, Spain
Barbara Mason, The Scripps Research Institute, La Jolla, United States
Jay McLaughlin, University of Florida, Gainsville, United States
Marisela Morales, National Institute on Drug Abuse, Bethesda, United States
Tomohisa Mori, Hoshi University, Shinagawa, Japan
Jose A Moron, Washington University in St. Louis, St. Louis, United States
James O’Callaghan, Centers for Disease Control & Prevention, Atlanta, United States
Nagarkatti Prakash, University of South Carolina, Columbia, United States
Subhash Pandey, University of Illinois at Chicago, Chicago, United States
Frederico Pereira, University of Coimbria, Coimbria, Portugal
Sabita Roy, University of Miami, Coral Gables, United States
Dipak Sarkar, Rutgers University, New Brunswick, United States
Susan Schenk, Victoria University of Wellington, Wellington, New Zealand
Stephanie Sillivan, Temple University, Philadelphia, United States
Nicola Simola, University of Cagliari, Cagliari, Italy
Edith Sullivan, Stanford University, Stanford, United States
Adriana Tagliaferro, Kean University, Union, United States
Michal Toborek, University of Miami, Coral Gables, United States
Lawrence Toll, Florida Atlantic University, Boca Raton, United States
Richard Van Rijn, Purdue University, West Lafayette, United States
Leandro Vendruscolo, National Institute on Drug Abuse, Bethesda, United States
Mohamed Ashraf Virmani, Alfasigma Nederland B.V., Utrecht, Netherlands
Yu-Jun Wang, Chinese Academy of Sciences, Shanghai, China
John Williams, Oregon Health Sciences University, Portland, United States
Ming Xu, University of Chicago, Chicago, United States
DEI Statement
At Advances in Drug & Alcohol Research, we believe in supporting human diversity. The journal is committed to informing and delivering basic and translational research with the ultimate goal of serving populations impacted by substance use and abuse globally. We welcome submissions from individuals of all ethnicities, abilities, ages, gender identities, nationalities, religions, sexual orientations, or other individual status or identity. We prioritize inclusivity at all stages of the research process, from manuscript submission to peer review, publication, and dissemination. As these principles require ongoing commitment, the journal will continue to work toward implementing best practice in scientific publishing and welcomes any feedback from our authors, editors, reviewers, readers, and community.
Open Access Statement
ADAR provides online free gold open access to the journal and all of its research publications.
Open Access funder and institutional mandates: ADAR is fully compliant with open access mandates, by publishing its articles under the Creative Commons Attribution licence (CC-BY). Funder mandates such as those by the Wellcome Trust (UK), National Institutes of Health (USA) and the Australian Research Council (Australia) are fully compatible with publishing in ADAR. Authors retain copyright of their work and can deposit their publication in any repository. The work can be freely shared and adapted provided that appropriate credit is given and any changes specified.
If the research contained in your published ADAR article was supported by the National Institutes of Health (NIH), another PMC designated funder, or a member of the Europe PMC funder group, you may self-deposit the article into PubMed Central after publication. Please see PubMed Central to determine your eligibility and for more information on how to begin this process.
Copyright Statement
Under the Conditions for Website Use and the General Conditions for Authors, authors of articles published in ADAR retain copyright on their articles, except for any third-party images and other materials added by ADAR, which are subject to copyright of their respective owners. Authors are therefore free to disseminate and re-publish their articles, subject to any requirements of third-party copyright owners and subject to the original publication being fully cited. Visitors may also download and forward articles subject to the citation requirements and subject to any fees ADAR’s publisher, Frontiers, may charge for downloading licenses. The ability to copy, download, forward or otherwise distribute any materials is always subject to any copyright notices displayed. Copyright notices must be displayed prominently and may not be obliterated, deleted or hidden, totally or partially.
Quality
Each ADAR article strives for the highest quality, thanks to genuinely collaborative interactions between authors, editors and reviewers. ADAR encourages authors to consult the instructions for authors guidelines prior to submission.
Contact
Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
For all queries regarding manuscripts in review, potential conflicts of interest, special issues, editorial board applications and any other questions, please contact adar.office@FrontiersPartnerships.org
IT HelpDesk
For technical issues, please contact our IT HelpDesk team at support@FrontiersPartnerships.org